Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Correction: Guggenheim Downgrades SpringWorks Therapeutics to Neutral, Lowers Price Target to $47 (Firm change from Stephens & Co. to Guggenheim)

Author: Benzinga Newsdesk | April 29, 2025 10:47am

Correction: Guggenheim analyst Michael Schmidt downgrades SpringWorks Therapeutics (NASDAQ:SWTX) from Buy to Neutral and lowers the price target from $77 to $47. (Analyst Firm change from Stephens & Co. to Guggenheim)

Posted In: SWTX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist